Screening and pharmacodynamic evaluation of the anti-respiratory syncytial virus activity of butene lactones in vitro and in vivo
© 2019 Wiley Periodicals, Inc..
A series of butene lactones were synthesized and these compounds were tested for anti-respiratory syncytial virus (RSV) activity in vitro. Three compounds exhibited an antiviral effect, the highest of which was compound 6b3 with an effective concentration 50% of 6.35 μM. The effects of 6b3 were then evaluated in vivo and a significant reduction in the lung index caused by RSV was detected. Reduced inflammatory infiltration and necrosis of the lungs were revealed by histopathology and gross pathology. Activation of an early immune response by 6b3 was also observed by cytokine analysis via a real-time polymerase chain reaction. These results indicated that 6b3 has an anti-RSV effect both in vitro and in vivo, and is a possible candidate compound for the development of an anti-RSV drug in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
|---|---|
| Enthalten in: |
Journal of medical virology - 92(2020), 1 vom: 08. Jan., Seite 17-25 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Zhenya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
25167-67-3 |
|---|
| Anmerkungen: |
Date Completed 10.03.2021 Date Revised 10.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.25586 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30085014X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30085014X | ||
| 003 | DE-627 | ||
| 005 | 20231225103414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.25586 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1002.xml |
| 035 | |a (DE-627)NLM30085014X | ||
| 035 | |a (NLM)31475735 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Zhenya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Screening and pharmacodynamic evaluation of the anti-respiratory syncytial virus activity of butene lactones in vitro and in vivo |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2021 | ||
| 500 | |a Date Revised 10.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 Wiley Periodicals, Inc. | ||
| 520 | |a A series of butene lactones were synthesized and these compounds were tested for anti-respiratory syncytial virus (RSV) activity in vitro. Three compounds exhibited an antiviral effect, the highest of which was compound 6b3 with an effective concentration 50% of 6.35 μM. The effects of 6b3 were then evaluated in vivo and a significant reduction in the lung index caused by RSV was detected. Reduced inflammatory infiltration and necrosis of the lungs were revealed by histopathology and gross pathology. Activation of an early immune response by 6b3 was also observed by cytokine analysis via a real-time polymerase chain reaction. These results indicated that 6b3 has an anti-RSV effect both in vitro and in vivo, and is a possible candidate compound for the development of an anti-RSV drug in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a EC50 | |
| 650 | 4 | |a RSV | |
| 650 | 4 | |a butene lactone | |
| 650 | 4 | |a molecular mechanism | |
| 650 | 7 | |a Alkenes |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Lactones |2 NLM | |
| 650 | 7 | |a butylene |2 NLM | |
| 650 | 7 | |a 25167-67-3 |2 NLM | |
| 700 | 1 | |a Tan, Yayun |e verfasserin |4 aut | |
| 700 | 1 | |a Mou, Xiaodong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Congcong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yuanyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Xiaoning |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hongmin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Haiwei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 92(2020), 1 vom: 08. Jan., Seite 17-25 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:92 |g year:2020 |g number:1 |g day:08 |g month:01 |g pages:17-25 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.25586 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 92 |j 2020 |e 1 |b 08 |c 01 |h 17-25 | ||